Summary
In a significant market movement during January 2022, Ori Biotech was the subject of a vc funding. The transaction achieved a gross valuation of £73,610,452. Leading the round was Novalis LifeSciences, Amadeus Capital Partners, Octopus Ventures, Delin Ventures, Northpond Ventures, Puhua Capital, Chimera Capital.
This transaction was brokered by an undisclosed advisor. The deal reflects ongoing market confidence within its sector.
Lead Investor / Acquirer
Novalis LifeSciences
Lead Investor / Acquirer
Amadeus Capital Partners
Lead Investor / Acquirer
Octopus Ventures
Lead Investor / Acquirer
Delin Ventures
Lead Investor / Acquirer
Northpond Ventures
Lead Investor / Acquirer
Puhua Capital
Lead Investor / Acquirer
Chimera Capital
Advising Broker
Undisclosed Firm
Related Deals in Healthcare & Biotech
Series B prioritisedOriginal Source
This funding round is sourced from the Tech.eu Funding Explorer. View the full record, investors, and citations there.
View on Tech.eu Funding ExplorerFunding data via Tech.eu Funding Explorer, licensed under CC BY 4.0. See our methodology.
AI Insight Lenses
ProAI-generated analysis from four professional perspectives. Powered by PE Deals.
Sign in to unlock AI Lenses
Sign in